February 27, 2015 10:26 AM ET


Company Overview of Selventa, Inc.

Company Overview

Selventa, Inc. operates as a biomarker discovery company for personalized healthcare. It offers SysDx, a molecular diagnostic test that harnesses molecular biological information, such as genomic, epigenomic, transcriptomic, proteomic, metabolomic, and electronic medical records to generate reports for physicians and patients. The company’s SysDx is used in autoimmune disorders, oncology, and infectious diseases. It also provides ClarifyRA, a blood-based predictive decision tool for rheumatologists; and ClarifyIBD, a blood-based predictive decision tool for gastroenterologists. Selventa, Inc. was formerly known as Genstruct, Inc. and changed its name to Selventa, Inc. in November 2010. The c...

One Alewife Center

Cambridge, MA 02140

United States

Founded in 2001





Key Executives for Selventa, Inc.

Chief Executive Officer and President
Co-Founder and Chairman of SAB
Chief Financial Officer
Senior Vice President of Research and Development
Chief Medical Officer
Compensation as of Fiscal Year 2014.

Selventa, Inc. Key Developments

Selventa, Inc. Presents at Biotech Showcase 2014, Jan-13-2014 08:00 AM

Selventa, Inc. Presents at Biotech Showcase 2014, Jan-13-2014 08:00 AM. Venue: Parc 55 Wyndham Union Square Hotel, San Francisco, California, United States. Speakers: David De Graaf, Chief Executive Officer and President.

YarcData Aligns With Selventa to Help Pharmaceutical Companies Deliver Personalized Medicine

YarcData announced a collaborative effort with Selventa. Selventa will have access to YarcData's big data analytics appliance, Urika(R), to help pharmaceutical organizations better target drugs, condense the time needed for new drug discoveries and accelerate market delivery. The YarcData Urika platform is a purpose-built, real-time appliance for automated data discovery that provides graph-optimized hardware and a graph database optimized for the underlying hardware enabling applications to interact with the appliance. Although it can be provisioned and managed by IT as any other Linux server, Urika is a highly scalable, real-time accelerated data discovery platform that augments existing systems, bringing data silos together to support ad hoc queries, pattern-based searches, inferencing and deduction. Because graph databases are more flexible than traditional systems, value can be extracted almost immediately, without waiting for months to build the ontology and load all of the data. The combined YarcData and Selventa solution will provide the opportunity for pharmaceutical companies to explore data discoveries across disease areas. Traditional databases are usually partitioned by disease area in order to limit the size of the database and make searching more manageable. Because data loaded into Urika does not need to be partitioned, the solution will enable analysis to be performed across larger or combined data sets, making it possible to find previously unknown relationships between genes and proteins, treatments and disease mechanisms, human and animal biology, diseased tissue and blood, as well as identification of biomarkers representative of predictive and prognostic indications.

Seegene, Inc. and Selventa, Inc. Form Strategic Collaboration to Develop Novel Molecular Diagnostics

Seegene, Inc. and Selventa, Inc. announced that they have entered into a strategic collaboration to develop novel molecular diagnostics in underserved diagnostic markets including autoimmune, cancer and infectious diseases. The synergistic combination of Selventa’s Systems Diagnostics (SysDx™) multi-omic analytics platform and Seegene’s TOCE™ and DPO™ multiplex PCR technology will result in powerful new MoDx that accelerate the adoption of personalized medicine in major classes of disease. Selventa’ SysDx works by analyzing a holistic range of a patient’s molecular information (e.g., genomic, epigenomic, transcriptomic, proteomic, metabolomic, and electronic medical record information) to identify a panel of “multi-omic” biomarkers that can accurately diagnose a patient’s disease and response or non-response to a therapy. By leveraging a powerful, first-in-class multiplexing technology, SysDx’s multi-omic biomarker approach can be the basis for a range of high value MoDx. Seegene’s qTOCE technology provides real-time simultaneous detection and quantification of multiple targets in a single channel (“one channel – many targets”). qTOCE can work with any qPCR instrument to differentiate as many as 7 targets per channel from a single sample, in a single reaction. qTOCE enables multiplex assay development across a wide range of applications, including high-multiplex quantitative real-time PCR and highly selective mutational analysis.

Similar Private Companies By Industry

Company Name Region
Symphony Dynamo, Inc. United States
Spectra Stable Isotopes United States
GenWay Biotech, Inc. United States
AzurRx BioPharma, Inc. United States
Metabolic Research, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Selventa, Inc., please visit www.selventa.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.